{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:53:40Z","timestamp":1790747620834,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"23-24","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.cca.2010.07.038","type":"journal-article","created":{"date-parts":[[2010,8,15]],"date-time":"2010-08-15T08:35:02Z","timestamp":1281861302000},"page":"1906-1914","source":"Crossref","is-referenced-by-count":91,"title":["How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?"],"prefix":"10.1016","volume":"411","author":[{"given":"Christiane","family":"Auray-Blais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aim\u00e9","family":"Ntwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe T.R.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Warnock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Paulo","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Millington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Bichet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sirrs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"West","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuh-Liang","family":"Hwu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan M.","family":"Keutzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X. Kate","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2010.07.038_bb0005","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-146-6-200703200-00007","article-title":"Narrative review: Fabry disease","volume":"146","author":"Clarke","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cca.2010.07.038_bb0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2010.07.038_bb0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cca.2010.07.038_bb0020","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-138-4-200302180-00014","article-title":"Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy","volume":"138","author":"Desnick","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cca.2010.07.038_bb0025","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF01606034","article-title":"Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy","volume":"417","author":"Elleder","year":"1990","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"10.1016\/j.cca.2010.07.038_bb0030","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1523-1755.2003.00160.x","article-title":"Fabry disease: detection of undiagnosed hemodialysis patients and identification of a \u201crenal variant\u201d phenotype","volume":"64","author":"Nakao","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.cca.2010.07.038_bb0035","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial","volume":"285","author":"Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2010.07.038_bb0040","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2010.07.038_bb0045","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting","volume":"21","author":"Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cca.2010.07.038_bb0050","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","article-title":"Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease","volume":"93","author":"Auray-Blais","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2010.07.038_bb0055","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ymgme.2009.04.006","article-title":"Gb3\/creatinine biomarkers for Fabry disease: issues to consider","volume":"97","author":"Auray-Blais","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2010.07.038_bb0060","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1080\/08035320510031045","article-title":"Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey","volume":"94","author":"Schaefer","year":"2005","journal-title":"Acta Paediatr Suppl"},{"key":"10.1016\/j.cca.2010.07.038_bb0065","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course","volume":"81","author":"Branton","year":"2002","journal-title":"Medicine"},{"key":"10.1016\/j.cca.2010.07.038_bb0070","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10545-006-0484-8","article-title":"The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 concentrations","volume":"30","author":"Vedder","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cca.2010.07.038_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease\u2014role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cca.2010.07.038_bb0080","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.cca.2010.07.038_bb0085","doi-asserted-by":"crossref","first-page":"2976","DOI":"10.1016\/j.jchromb.2009.07.008","article-title":"Normal phase liquid chromatography coupled to quadrupole time-of-flight atmospheric pressure chemical ionization mass spectrometry for separation, detection and mass spectrometric profiling of neutral sphingolipids and cholesterol","volume":"877","author":"Farwanah","year":"2009","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.cca.2010.07.038_bb0090","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10545-005-5263-4","article-title":"Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease","volume":"28","author":"Mills","year":"2005","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cca.2010.07.038_bb0095","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10545-009-1055-6","article-title":"Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease","volume":"32","author":"Auray-Blais","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cca.2010.07.038_bb0100","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s10545-006-0444-3","article-title":"Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease","volume":"30","author":"Auray-Blais","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.cca.2010.07.038_bb0105","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1373\/clinchem.2008.104711","article-title":"Multiplex enzyme assay screening of dried blood spots for lysosomal storage disorders by using tandem mass spectrometry","volume":"54","author":"Zhang","year":"2008","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2010.07.038_bb0110","first-page":"207","article-title":"Determination of creatinine by means of automatic chemical analysis","volume":"30","author":"Chasson","year":"1960","journal-title":"Tech Bull Regist Med Technol"},{"key":"10.1016\/j.cca.2010.07.038_bb0115","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMra054415","article-title":"Assessing kidney function\u2014measured and estimated glomerular filtration rate","volume":"354","author":"Stevens","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2010.07.038_bb0120","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cca.2010.07.038_bb0125","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta","volume":"18","author":"Tahir","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.cca.2010.07.038_bb0130","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","article-title":"Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy","volume":"24","author":"Schiffmann","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cca.2010.07.038_bb0135","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease","volume":"20","author":"West","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.cca.2010.07.038_bb0140","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2215\/CJN.06090809","article-title":"Biomarkers of Fabry disease nephropathy","volume":"5","author":"Schiffmann","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cca.2010.07.038_bb0145","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ymgme.2009.04.009","article-title":"Fabry disease urinary globotriaosylceramide\/creatinine biomarker evaluation by liquid chromatography\u2013tandem mass spectrometry in healthy infants from birth to 6months","volume":"97","author":"Barr","year":"2009","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2010.07.038_bb0150","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1136\/jmg.33.8.682","article-title":"Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene","volume":"33","author":"Redonnet-Vernhet","year":"1996","journal-title":"J Med Genet"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898110005024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898110005024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T20:59:52Z","timestamp":1544302792000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898110005024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":30,"journal-issue":{"issue":"23-24","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0009898110005024"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2010.07.038","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}